Francisco Portela

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6029290/publications.pdf

Version: 2024-02-01

50 papers 1,957 citations

471509 17 h-index 243625 44 g-index

52 all docs 52 docs citations

times ranked

52

2769 citing authors

#	Article	IF	CITATIONS
1	The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Special situations. Journal of Crohn's and Colitis, 2010, 4, 63-101.	1.3	695
2	Second European evidence-based consensus on the diagnosis and management of ulcerative colitis Part 3: Special situations. Journal of Crohn's and Colitis, 2013, 7, 1-33.	1.3	422
3	Review of the disease course among adult ulcerative colitis population-based longitudinal cohorts. Inflammatory Bowel Diseases, 2012, 18, 573-583.	1.9	116
4	Management of Inflammatory Bowel Disease with Infliximab and Other Anti-Tumor Necrosis Factor Alpha Therapies. BioDrugs, 2010, 24, 3-14.	4.6	84
5	WSES guidelines for management of Clostridium difficile infection in surgical patients. World Journal of Emergency Surgery, 2015, 10, 38.	5.0	78
6	Capsule endoscopy in inflammatory bowel disease type unclassified and indeterminate colitis serologically negative. Inflammatory Bowel Diseases, 2010, 16, 1663-1668.	1.9	45
7	Phenotype–Genotype Profiles in CrohnÊ⅓s Disease Predicted by Genetic Markers in Autophagy-Related Genes (GOIA Study II). Inflammatory Bowel Diseases, 2013, 19, 230-239.	1.9	37
8	Terminal ileitis in a renal transplanted patient. Inflammatory Bowel Diseases, 2011, 17, E52-E53.	1.9	31
9	Surveillance in Ulcerative Colitis. Inflammatory Bowel Diseases, 2014, 20, 2038-2045.	1.9	29
10	Ulcerative colitis in northern Portugal and Galicia in Spain. Inflammatory Bowel Diseases, 2010, 16, 1227-1238.	1.9	27
11	Impact of Infliximab and Cyclosporine on the Risk of Colectomy in Hospitalized Patients with Ulcerative Colitis Complicated by Cytomegalovirusâ€"A Multicenter Retrospective Study. Inflammatory Bowel Diseases, 2017, 23, 1605-1613.	1.9	27
12	Left-Sided Portal Hypertension: A Sinister Entity. GE Portuguese Journal of Gastroenterology, 2015, 22, 234-239.	0.8	25
13	Comparing the Continuous Geboes Score With the Robarts Histopathology Index: Definitions of Histological Remission and Response and their Relation to Faecal Calprotectin Levels. Journal of Crohn's and Colitis, 2020, 14, 169-175.	1.3	25
14	Inflammatory bowel disease: adherence to immunomodulators in a biological therapy era. European Journal of Gastroenterology and Hepatology, 2016, 28, 1313-1319.	1.6	24
15	CrohnÊ $\frac{1}{4}$ s disease in a southern European country: Montreal classification and clinical activity. Inflammatory Bowel Diseases, 2009, 15, 1343-1350.	1.9	22
16	Development and Validation of Risk Matrices for Crohn's Disease Outcomes in Patients Who Underwent Early Therapeutic Interventions. Journal of Crohn's and Colitis, 2017, 11, jjw171.	1.3	20
17	Anaemia in Patients with Inflammatory Bowel Disease - A Nationwide Cross-Sectional Study. Digestion, 2016, 93, 214-220.	2.3	18
18	Development and Validation of Risk Matrices Concerning Ulcerative Colitis Outcomes—Bayesian Network Analysis. Journal of Crohn's and Colitis, 2019, 13, 401-409.	1.3	17

#	Article	IF	Citations
19	CARD15 mutations and colorectal cancer in a South European country. International Journal of Colorectal Disease, 2010, 25, 1211-1219.	2.2	16
20	Ulcerative colitis in a Southern European country: A national perspective. Inflammatory Bowel Diseases, 2010, 16, 822-829.	1.9	15
21	NOD2 gene mutations in ulcerative colitis: useless or misunderstood?. International Journal of Colorectal Disease, 2014, 29, 653-661.	2.2	15
22	Hospitalization trends of the Inflammatory Bowel Disease landscape: A nationwide overview of 16 years. Digestive and Liver Disease, 2019, 51, 952-960.	0.9	15
23	CARD15 Mutations and Perianal Fistulating Crohn's Disease: Correlation and Predictive Value of Antibiotic Response. Digestive Diseases and Sciences, 2011, 56, 853-859.	2.3	14
24	The risk of disabling, surgery and reoperation in Crohn's disease – A decision tree-based approach to prognosis. PLoS ONE, 2017, 12, e0172165.	2.5	14
25	Hidden musculoskeletal involvement in inflammatory bowel disease: a multicenter ultrasound study. BMC Musculoskeletal Disorders, 2016, 17, 84.	1.9	13
26	Endoscopic treatment of bleeding gastric varices with histoacryl (N-butyl-2-cyanoacrylate): a South European single center experience. Indian Journal of Gastroenterology, 2013, 32, 227-231.	1.4	12
27	The who-when-why triangle of complementary and alternative medicine use among Portuguese IBD patients. Digestive and Liver Disease, 2017, 49, 388-396.	0.9	10
28	Rapid test detection of anti-infliximab antibodies: performance comparison with three different immunoassays. Therapeutic Advances in Gastroenterology, 2020, 13, 175628482096579.	3.2	9
29	Ulcerative Colitis: Are We Neglecting Its Progressive Character. GE Portuguese Journal of Gastroenterology, 2018, 25, 74-79.	0.8	7
30	Incidence Trends of Inflammatory Bowel Disease in a Southern European Country: A Mirror of the Western World?. Clinical and Translational Gastroenterology, 2022, 13, e00481.	2.5	7
31	Clinical practice in Crohn's disease in bordering regions of two countries: Different medical options, distinct surgical events. Journal of Crohn's and Colitis, 2010, 4, 301-311.	1.3	6
32	Predictive value of rectal aberrant crypt foci for intraepithelial neoplasia in ulcerative colitis – a cross-sectional study. Scandinavian Journal of Gastroenterology, 2014, 49, 1219-1229.	1.5	6
33	Primary leiomyoma of the liver: accurate preoperative diagnosis on liver biopsy. BMJ Case Reports, 2009, 2009, bcr0920080898-bcr0920080898.	0.5	6
34	Endoscopic ultrasound-guided ethanol ablation therapy for pancreatic insulinoma: an unusual strategy. Endocrinology, Diabetes and Metabolism Case Reports, 2017, 2017, .	0.5	6
35	Meningitis in a Patient with Previously Undiagnosed Crohn $\hat{E}^{1}\!\!/\!\!4$ s Disease. Inflammatory Bowel Diseases, 2009, 15, 643-645.	1.9	5
36	<i>Card15</i> mutations and gastric cancer in a Portuguese population. Scandinavian Journal of Gastroenterology, 2013, 48, 1188-1197.	1.5	5

#	Article	IF	CITATIONS
37	The timing of early therapeutic strategies has a significant impact on Crohn's disease prognosis. Digestive and Liver Disease, 2018, 50, 462-468.	0.9	5
38	Age at Diagnosis Is Determinant for the Outcome of Inflammatory Bowel Disease: Is It a Myth?. Clinical and Translational Gastroenterology, 2021, 12, e00309.	2.5	5
39	Fulminant colitis. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2013, 27, 771-782.	2.4	4
40	latrogenic Perforations During Colonoscopy In a Portuguese Population: A Study Including In and Out-Of-Hospital Procedures. GE Portuguese Journal of Gastroenterology, 2016, 23, 183-190.	0.8	3
41	Inflammatory Bowel Disease Reoperation Rate Has Decreased Over Time If Corrected by Prevalence. Clinical and Translational Gastroenterology, 2020, 11, e00227.	2.5	3
42	Necrotizing external otitis on a Crohn's disease patient treated with infliximab. Journal of Crohn's and Colitis, 2010, 4, 215-216.	1.3	2
43	Rare cause of fever in a patient with ulcerative colitis. Inflammatory Bowel Diseases, 2011, 17, E64-E65.	1.9	2
44	Health-Related Quality of Life in Patients with Moderate to Severe Ulcerative Colitis: Surgical Intervention versus Immunomodulatory Therapy. Digestion, 2020, 101, 631-637.	2.3	2
45	Sweet's Syndrome as Manifestation of Active Ulcerative Colitis. GE Portuguese Journal of Gastroenterology, 2020, 27, 138-140.	0.8	2
46	Role of Intestinal Ultrasound in the Evaluation of Postsurgical Recurrence in Crohn's Disease: Correlation with Endoscopic Findings. GE Portuguese Journal of Gastroenterology, 0, , 1-9.	0.8	2
47	Fecal microbiota transplantation in recurrent Clostridium difficile infection in a patient with concomitant inflammatory bowel disease. Revista Espanola De Enfermedades Digestivas, 2017, 109, 473-476.	0.3	2
48	Posttransplant Lymphoproliferative Disorders in Patients with IBD on Immunosuppressive Treatment. Inflammatory Bowel Diseases, 2009, 15, 481-483.	1.9	0
49	Rehospitalization rates, costs, and risk factors for inflammatory bowel disease: a 16-year nationwide study. Therapeutic Advances in Gastroenterology, 2020, 13, 175628482092383.	3.2	0
50	Burden of Disease and Cost of Illness of Inflammatory Bowel Diseases in Portugal. GE Portuguese Journal of Gastroenterology, 2023, 30, 283-292.	0.8	0